Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2006-01-10
2006-01-10
Leary, Louise N. (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S968000, C435S004000
Reexamination Certificate
active
06984498
ABSTRACT:
A cancer screening method is provided, wherein the method is characterized by administering a compound to a patient, the compound being a complex of a fluorescent marker and a radioactive marker, in a dose emitting between 5 Gy and 20 Gy radiation. Cells are then collected preferably through non-invasive or minimally invasive means. If fluorescence is observed in the exfoliated cells, tomographic scanning is conducted to further locate and/or confirm suspected malignant areas or metastatic areas. Further observation or treatment may be conducted either through fluorescence guided endoscopy, photo-dynamic therapy, and/or radiation treatment.
REFERENCES:
patent: 3394369 (1968-07-01), Johnston, Jr.
patent: 3846490 (1974-11-01), Aronova et al.
patent: 3973129 (1976-08-01), Blumberg et al.
patent: 4772691 (1988-09-01), Herman
patent: 4886831 (1989-12-01), Morcos et al.
patent: 4897444 (1990-01-01), Brynes et al.
patent: 4905670 (1990-03-01), Adair
patent: 4920143 (1990-04-01), Levy et al.
patent: 4977177 (1990-12-01), Bommer et al.
patent: 4997639 (1991-03-01), Aizawa et al.
patent: 5026368 (1991-06-01), Adair
patent: 5043101 (1991-08-01), Gordon
patent: 5079262 (1992-01-01), Kennedy et al.
patent: 5087636 (1992-02-01), Jamieson et al.
patent: 5117466 (1992-05-01), Buican et al.
patent: 5122453 (1992-06-01), Martin et al.
patent: 5143054 (1992-09-01), Adair
patent: 5149708 (1992-09-01), Dolphin et al.
patent: 5162231 (1992-11-01), Cole et al.
patent: 5211938 (1993-05-01), Kennedy et al.
patent: 5234940 (1993-08-01), Kennedy et al.
patent: 5251613 (1993-10-01), Adair
patent: 5270171 (1993-12-01), Cercek et al.
patent: 5283255 (1994-02-01), Levy et al.
patent: 5308608 (1994-05-01), Dolphin et al.
patent: 5308861 (1994-05-01), Aizawa et al.
patent: 5391547 (1995-02-01), Cole et al.
patent: 5418169 (1995-05-01), Crissman et al.
patent: 5422093 (1995-06-01), Kennedy et al.
patent: 5441531 (1995-08-01), Zarate et al.
patent: 5554505 (1996-09-01), Hajek et al.
patent: 5556764 (1996-09-01), Sizto et al.
patent: 5591422 (1997-01-01), Hemmi et al.
patent: 5605805 (1997-02-01), Verwer et al.
patent: 5616342 (1997-04-01), Lyons
patent: 5627040 (1997-05-01), Bierre et al.
patent: 5652114 (1997-07-01), Chu et al.
patent: 5773609 (1998-06-01), Robinson et al.
patent: 5955490 (1999-09-01), Kennedy et al.
patent: 6190877 (2001-02-01), Adair
patent: 6235767 (2001-05-01), Kelly et al.
patent: 6316215 (2001-11-01), Adair et al.
patent: 6358989 (2002-03-01), Kunz et al.
patent: 6387350 (2002-05-01), Goldenberg
patent: 6395016 (2002-05-01), Oron et al.
patent: 6422988 (2002-07-01), Bradshaw et al.
patent: 6422989 (2002-07-01), Hektner
patent: 6566517 (2003-05-01), Miura et al.
patent: 6750037 (2004-06-01), Adair et al.
patent: 0 277 837 (1988-10-01), None
patent: 04330013 (1992-11-01), None
Abstract, Mu Y, et al., “P-S-D-007 Luminescence in the Diagnosis of Exfoliative Cells from Malignant Tumors”, X-P-0021614131, vol. 9, No. 4, 1987, pp. 258-259.
Abstract, Schwartz, G., et al., “Selected Amino Acridines as Fluorescent Probes in Cytochemistry in General and in the Detection of Cancer Cells in Particular”,Analytical and Quantitative Cytology, vol. 4, No. 1, 1982, pp. 44-54.
Abstract, Gardiner, R.A., et al., “Abnormal prostatic cells in ejaculates from men with prostatic cancer: A preliminary report”,British Journal of Urology, vol. 78, No. 3, 1996, pp. 414-418.
Abstract, Bologna, M., et al., “Improved tissue culture method for the study of prostatic carcinoma: A significant diagnostic tool.”,Pathology Research and Practice, vol. 191, No. 9, 1995, pp. 899-903.
Artemov et al.,Cancer Res., 61:3039-3044 (2001).
Fiel et al.,Cancer Letters, 40:23-32 (1988).
Furmanski and Longley,Cancer Res., 48:4604-4610 (1988).
Harisinghani et al.,N. Engl. J. Med., 348(25):2491-2499 (2003).
Koenig et al.,Magnetic Resonance in Medicine, 4:252-260 (1987).
Lyon et al.,Magnetic Resonance in Medicine, 4:24-33 (1987).
Rosenthal et al.,Clin. Cancer Res., 5:739-745 (1999).
van Zijl et al.,Acta Radiologica, 374(supp):75-79 (1990).
Pottier et al.; “Non-Invasive Technique for Obtaining Fluorescence Excitation and Emission SpectraIn Vivo”; Photochemistry and Photobiology; vol. 44, No. 5; pps. 679-687, 1986.
Abstract, Sauter, E.R., et al., “Nipple aspirate fluid: A promising non-invasive method to Identify cellular markers of breast cancer risk”,British Journal of Cancer, vol. 76, 1997, pp. 494-501.
Abstract, Sugiyama, M., et al., “Non-invasive detection of bladder cancer by identification of abnormal CD44 proteins in exfoliated cancer cells in urine”, Abstract,Clinical Molecular Pathology, 1995, vol. 48, pp. M142-M147.
Nyamekye et al.; “Photodynamic Therapy of Normal and Ballon-Injured Rat Carotid Arteries Using 5-Amino-Levulinic Acid”;Circulation, vol. 91, No. 2, Jan. 15, 1995, pp. 417-425.
Peng et al.; “5-Aminolevulinic Acid-Based Photodynamic Therapy”;American Cancer Society; 1997; pp. 2282-2305.
Berg et al.; “The Influence of Iron Chelators On the Accumulation of Protoporphyrin IX in 5-Aminolaevulinic Acid-Treated Cells”;British Journal of Cancer; 1996; pp. 688-697.
Noodt et al.; “Apoptosis and Necrosis Induced With Light and 5-Aminolaevulinic Acid-Derived Protoporphyrin IX”;Flow Cytometry; 1996; pp. 22-29.
Malik et al.; “Destruction of Erythroleukaemic Cells by Photoactivation of Endogenous Porphyrins”British Journal of Cancer; 1987; 56; pp. 589-595.
Leon et al.; “Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Rcurrence of Restenosis After Stenting”;The New England Journal of Medicine; Jan. 25, 2001; 344(4); pp. 250-256.
Verin et al.; “Endoluminal Beta-Radiation Therapy for the Prevention of Coronary Restenosis After Balloon Angioplasty”;The New England Journal of Medicine; Jan. 25, 2002; 344(4); pp. 243-249.
Abstract: Leunig et al.; “Fluorescence Photodetection of Neoplastic Lesions in the Oral Cavity Following Topical Application of 5-Aminolevulinic Acid”;Laryngo-Rhino-Otologie; vol. 75, No. 8, Aug. 1996; pp. 459-464.
Firnau et al.; “64Cu Labelling of Hematoporphyrin Derivative for Non-Invasive In-Vivo Measurements of Tumour Uptake”Porphyin Localizatikon and Treatment of Tumors; 1984 Alan R. Liss, Inc.; pp. 629-636.
Webster's II New Riverside University Dictionary, Copyright 1984, 1988, 1994, pp. 490 and 968.
News and Views; Radiolabelled photosensitizers for tumour imaging and photodynamic therapy, B.C. Wilson and J.E. VanLier; XPOO8023295, 459-463.
The Biological Characteristics of a Water Solube Porphyrin in Rat Lymph Nodes; D.A. Cole, J.A. Mercer-Smith, S.A. Schreyer, J.K. Norman and D.K. Lavallee; XP008023296, 457-464.
Porphyrin Localization and Treatment of Tumors, pp. 629-636; 1984 Alan R. Liss, Inc., XP0080239292.
Chromatographic Analysis and tissue Distribution of Radiocopper-Labelled Haematoporphyrin Derivatives; Brian C. Wilson, Gunter Firnau, W. Patrick Jeeves, Kay L. Brown, Diane M. Bums-McCormick; XP008023291, 72-79.
Leary Louise N.
Sheridan Ross PC
LandOfFree
Method of cancer screening primarily utilizing non-invasive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of cancer screening primarily utilizing non-invasive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of cancer screening primarily utilizing non-invasive... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3559859